-$0.29 Earnings Per Share Expected for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) This Quarter

Brokerages expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) will announce earnings of ($0.29) per share for the current quarter, Zacks reports. Two analysts have made estimates for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share’s earnings, with estimates ranging from ($0.35) to ($0.22). Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share posted earnings of $0.11 per share during the same quarter last year, which indicates a negative year over year growth rate of 363.6%. The firm is expected to issue its next quarterly earnings results on Tuesday, March 6th.

On average, analysts expect that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will report full year earnings of $1.39 per share for the current financial year, with EPS estimates ranging from $1.30 to $1.46. For the next year, analysts forecast that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.86) to ($0.74). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.09 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.13. The firm had revenue of $39.68 million for the quarter, compared to analysts’ expectations of $38.22 million. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a net margin of 44.47% and a return on equity of 33.92%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.08) earnings per share.

Several research analysts have recently weighed in on AVDL shares. Ladenburg Thalmann Financial Services upped their price target on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from $27.00 to $30.00 in a report on Thursday, September 7th. Langenberg & Company reaffirmed a “buy” rating and issued a $30.00 price target (up previously from $27.00) on shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in a report on Thursday, September 7th. Zacks Investment Research cut shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, BidaskClub raised shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.75.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL) opened at $8.03 on Friday. The firm has a market cap of $322.68, a price-to-earnings ratio of 4.16 and a beta of 1.34. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 1-year low of $7.52 and a 1-year high of $12.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.53 and a quick ratio of 1.47.

In related news, Director Craig R. Stapleton sold 254,265 shares of the stock in a transaction on Monday, November 27th. The stock was sold at an average price of $9.35, for a total value of $2,377,377.75. Following the transaction, the director now owns 253,413 shares of the company’s stock, valued at $2,369,411.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael S. Anderson bought 5,000 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock in a transaction that occurred on Thursday, December 7th. The stock was purchased at an average cost of $8.86 per share, for a total transaction of $44,300.00. The disclosure for this purchase can be found here. 5.07% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVDL. PNC Financial Services Group Inc. increased its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 2,484.0% in the second quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after acquiring an additional 10,532 shares during the last quarter. Nine Chapters Capital Management LLC bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter valued at $132,000. Sei Investments Co. increased its stake in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 29.5% in the second quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after acquiring an additional 2,900 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the second quarter valued at $181,000. Finally, Cubist Systematic Strategies LLC bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share in the third quarter valued at $184,000. 67.75% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/24/0-29-earnings-per-share-expected-for-avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-this-quarter.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Get a free copy of the Zacks research report on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL)

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit